BACE1 and Alzheimer disease: The levels of miR-107 that targets BACE1 are reduced in the temporal cortex not only of AD but also of the patients affected with mild cognitive impairment (MCI), a prodrome of AD, indicating that downregulation of miR-107 begins at the very early stage of AD[55].